First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™¹

Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer²

WAYNE, Pa.--(BUSINESS WIRE)--May 21, 2026-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.

In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026.

Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in StockholmMay 15 – 19 highlight early patient experience following BPH treatment¹ with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.²

CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System*

At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezūm™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.¹

The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.¹

Key study endpoints of the study:

• Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezūm™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively¹
• Early patient experience was better for the UroLift™ System patients compared to Rezūm™ patients¹
• UroLift™ System and Rezūm™ subjects had similar durability through 12 months¹
• Patients’ sexual function^† was preserved through 12 months with the UroLift™ System¹

“What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y.

Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity*

At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.²

Key endpoints of the study:

• Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm²
• Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control²

These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.²

“The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.” ²

“These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.”

About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,³ relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.^4,5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.^†6-7 A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.⁸ Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.⁹ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.¹⁰ Learn more at www.UroLift.com.

UroLift System Important Safety Information
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates ≤100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com.

About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.¹¹ Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).¹²

Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.^13,14

Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy¹¹ and is cleared for rectal spacing in the United States, Australia, and Europe.¹⁵ Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters.

Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.

It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.

Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

About Interventional Urology
The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel™ rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift™ System for men suffering from BPH symptoms, and Deflux™ injectable gel for children with grades II-V vesicoureteral reflux (VUR).

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2026 Teleflex Incorporated. All rights reserved. APM1495A

*Studies sponsored by Teleflex.

**Drs. Chughtai and King are paid consultants of Teleflex

†No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

References

1. Chughtai et al. J Urol 2026
2. King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623.
3. Shore, Can J Urol 2014
4. Rukstalis, Prostate Cancer Prostatic Dis 2018
5. UroLift™ System Instructions for Use
6. AUA BPH Guidelines 2003, 2020
7. McVary, Urology 2019
8. Roehrborn, Can J Urol 2017
9. Roehrborn, J Urol 2013
10. Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology.
11. Mariados NF, Orio PF III, King M et al. JAMA Oncol (2023)*,**
12. Barrigel Injectable Gel Instructions for Use (2022)
13. Svatos M, Chell E, Low DA et al. Med Phys (2024)*,**
14. Restylane^® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021.
15. Data on file Teleflex. 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521235608/en/

Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836

Source: Teleflex Incorporated